Combination of 18F-FDG PET/CT and diffusion-weighted mr imaging as a predictor of histologic response to neoadjuvant chemotherapy: Preliminary results in osteosarcoma

Journal of Nuclear Medicine

Volumn 54, Issue 7, 2013, Pages 1053-1059

  Byun, Byung Hyun ^a   Kong, Chang Bae ^a   Lim, Ilhan ^a   Choi, Chang Woon ^a   Song, Won Seok ^a   Cho, Wan Hyeong ^a   Jeon, Dae Geun ^a   Koh, Jae Soo ^a   Lee, Soo Yong ^a   Lim, Sang Moo ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

ADC; Chemotherapy; MR imaging; Osteosarcoma; PET

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GADODIAMIDE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; METHOTREXATE; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; APPARENT DIFFUSION COEFFICIENT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE SCANNER; OSTEOSARCOMA; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STANDARDIZED UPTAKE VALUE; TUMOR VOLUME; ADC; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; BONE TUMOR; CHEMOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; IMAGE SUBTRACTION; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PET; PILOT STUDY; PROGNOSIS; REPRODUCIBILITY; TREATMENT OUTCOME; VERY ELDERLY;

ADC; CHEMOTHERAPY; MR IMAGING; OSTEOSARCOMA; PET;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DIFFUSION MAGNETIC RESONANCE IMAGING; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOADJUVANT THERAPY; OSTEOSARCOMA; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879947610     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.115964     Document Type: Article

References (31)

1. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer. 2005;41:2836-2845.
2. Uhl M, Saueressig U, Koehler G, et al. Evaluation of tumour necrosis during chemotherapy with diffusion-weighted MR imaging: preliminary results in osteosarcomas. Pediatr Radiol. 2006;36:1306-1311.
3. Bajpai J, Gamnagatti S, Kumar R, et al. Role of MR imaging in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis. Pediatr Radiol. 2011;41:441-450.
4. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423-431.
5. Söderlund V, Larsson SA, Bauer HC, Brosjo O, Larsson O, Jacobsson H. Use of 99mTc-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy. Eur J Nucl Med. 1997;24:511-515.
6. Wellings RM, Davies AM, Pynsent PB, Carter SR, Grimer RJ. The value of computed tomographic measurements in osteosarcoma as a predictor of response to adjuvant chemotherapy. Clin Radiol. 1994;49:19-23.
7. Oka K, Yakushiji T, Sato H, Hirai T, Yamashita Y, Mizuta H. The value of diffusion-weighted imaging for monitoring the chemotherapeutic response of osteosarcoma: a comparison between average apparent diffusion coefficient andminimum apparent diffusion coefficient. Skeletal Radiol. 2010;39:141-146.
8. Hayashida Y, Yakushiji T, Awai K, et al. Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results. Eur Radiol. 2006;16:2637-2643.
9. Im HJ, Kim TS, Park SY, et al. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma. Eur J Nucl Med Mol Imaging. 2012;39:39-49.
10. Cheon GJ, Kim MS, Lee JA, et al. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PETandMR imaging. J Nucl Med. 2009;50:1435-1440.
11. Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med. 1999;40:1637-1643.
12. Choi SY, Chang YW, Park HJ, Kim HJ, Hong SS, Seo DY. Correlation of the apparent diffusion coefficiency values on diffusion-weighted imaging with prognostic factors for breast cancer. Br J Radiol. 2012;85:e474-e479.
13. Drzezga A, Souvatzoglou M, Eiber M, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53:845-855.
14. Delso G, Ziegler S. PET/MR imaging system design. Eur J Nucl Med Mol Imaging. 2009;36(suppl 1):S86-S92.
15. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MR imaging, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med. 2012;53:928-938.
16. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MR imaging, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med. 2012;53:1244-1252.
17. Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106 (suppl):55-67.
18. Kim MS, Lee SY, Cho WH, et al. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. Ann Surg Oncol. 2008;15:906-914.
19. Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 1996;14:848-858.
20. Coffin CM, Lowichik A, Zhou H. Treatment effects in pediatric soft tissue and bone tumors: practical considerations for the pathologist. Am J Clin Pathol. 2005;123:75-90.
21. Shultz EK. Multivariate receiver-operating characteristic curve analysis: prostate cancer screening as an example. Clin Chem. 1995;41:1248-1255.
22. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148: 839-843.
23. van der Woude HJ, Bloem JL, Hogendoorn PC. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities. Skeletal Radiol. 1998;27: 57-71.
24. Park SH, Moon WK, Cho N, et al. Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol. 2012;22:18-25.
25. Gong NJ, Wong CS, Chu YC, Gu J. Treatment response monitoring in patients with gastrointestinal stromal tumor using diffusion-weighted imaging: preliminary results in comparison with positron emission tomography/computed tomography. NMR Biomed. 2013;2:185-192.
26. Huang TL, Liu RS, Chen TH, Chen WY, Hsu HC, Hsu YC. Comparison between F-18-FDG positron emission tomography and histology for the assessment of tumor necrosis rates in primary osteosarcoma. J Chin Med Assoc. 2006;69: 372-376.
27. Brenner W, Bohuslavizki KH, Eary JF. PET imaging of osteosarcoma. J Nucl Med. 2003;44:930-942.
28. Werner MK, Schmidt H, Schwenzer NF. MR/PET: a new challenge in hybrid imaging. AJR. 2012;199:272-277.
29. Kinoshita M, Arita H, Goto T, et al. A novel PET Index, 18F-FDG-11C-methionine uptake decoupling score, reflects glioma cell infiltration. J Nucl Med. 2012; 53:1701-1708.
30. Koc Z, Erbay G, Ulusan S, Seydaoglu G, Aka-Bolat F. Optimization of b value in diffusion-weighted MR imaging for characterization of benign and malignant gynecological lesions. J Magn Reson Imaging. 2012;35:650-659.
31. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932-945.